Therabene
Therabene is a biotechnology company developing a novel class of high-potency, low-toxicity PROTAC molecules designed to target undruggable proteins for the treatment of cancers, autoimmune diseases, and certain viral infections. Their proprietary degraders, such as TB-008/TB-003B targeting CDK9 and TB-M-002 targeting Myc, are in preclinical development for aggressive cancers including triple-negative breast cancer, pancreatic cancer, and non-small cell lung cancer. The company leverages virtual screening, generative AI, and conventional lab practices to innovate beyond traditional drug discovery focused on protein activity control. Founded by Dr. Mario DiPaola, an experienced biotech executive with a strong track record in biologics and small molecule therapeutics, Therabene is actively seeking partnerships with academic, clinical, pharmaceutical, and biotech entities to advance their pipeline and clinical development.
Therabene
Therabene is a biotechnology company developing a novel class of high-potency, low-toxicity PROTAC molecules designed to target undruggable proteins for the treatment of cancers, autoimmune diseases, and certain viral infections. Their proprietary degraders, such as TB-008/TB-003B targeting CDK9 and TB-M-002 targeting Myc, are in preclinical development for aggressive cancers including triple-negative breast cancer, pancreatic cancer, and non-small cell lung cancer. The company leverages virtual screening, generative AI, and conventional lab practices to innovate beyond traditional drug discovery focused on protein activity control. Founded by Dr. Mario DiPaola, an experienced biotech executive with a strong track record in biologics and small molecule therapeutics, Therabene is actively seeking partnerships with academic, clinical, pharmaceutical, and biotech entities to advance their pipeline and clinical development.